Substituted nicotinamide compounds and uses thereof

Details Substituted nicotinamide compounds and uses thereof Substituted nicotinamide compounds and uses thereof

2008-09-17

2011-12-27

Davis, Zinna Northington (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S255000, C546S268100, C546S275400, C546S280400, C514S336000, C514S341000, C514S342000

Reexamination Certificate

active

08084470

ABSTRACT:
Substituted nicotinamide compounds corresponding to formula Ia process for their preparation, pharmaceutical compositions containing these compounds, and the use thereof for the treatment or inhibition conditions such as pain, epilepsy, migraine, anxiety states, or urinary incontinence.

REFERENCES:
patent: 6630495 (2003-10-01), Cooke et al.
patent: 2002/0128277 (2002-09-01), Dworetzky et al.
patent: WO 99/24404 (1999-05-01), None
patent: WO 2005/023802 (2005-03-01), None
G. Blackburn-Munro et al., “The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain”, European Journal of Pharmacology, 460 (2003) 109-116.
T. Coderre et al., “Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence”, Pain, 52 (1993) 259-285.
R. Dost et al., “The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation”, Naunyn-Schmiedeberg's Arch Pharmacol, (2004) 369: 382-390.
D. Dubuisson et al., “The Formalin Test: A Quantitative Study of the Analgesic Effects of Morphine, Meperidine, and Brain Stem Stimulation in Rats and Cats.” Pain, 4 (1977) 161-174.
V. Gribkoff, “The therapeutic potential of neuronal KCNQ channel modulators”, Expert Opinion Ther. Targets, (2003) 7(6): 737-748.
M.P.G. Korsgaard et al., “Anxiolytic Effects of Maxipost (BMS-204352) and Retigabine via Activation of Neuronal Kv7 Channels”, The Journal of Pharmacology and Experimental Therapeutics, vol. 314, No. 1, 2005, 282-292.
A. Nielsen et al., “Pharmacological characterisation of acid-induced muscle allodynia in rats”, European Journal of Pharmacology, 487 (2004) 93-103.
G. Passmore et al., “KCNQ/M Currents in Sensory Neurons: Significance for Pain Therapy”, The Journal of Neuroscience, Aug. 6, 2003, 23 (18): 7227-7236.
O.P. Hamill et al., “Improved Patch-Clamp Technologies for High-Resolution Current Recording from Cells and Cell-Free Membrane Patches”, European Journal of Physiology (1981) 391: 85-100.
T. Streng et al., “Urodynamic Effects of the K+ Channel (KCNQ) Opener Retigabine in Freely Moving, Conscious Rats”, The Journal of Urology, (2004) vol. 172, 2054-2058.
A. Wickenden et al., “KCNQ potassium channels: drug targets for the treatment of epilepsy and pain”, Expert Opinion Ther. Patents (2004) 14(4): 457-469.

Affiliated with

Also associated with

Rating

Substituted nicotinamide compounds and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted nicotinamide compounds and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted nicotinamide compounds and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4267930